Quick Ratio: Arcturus Therapeutics (ARCT)

This chart of the market value of Arcturus Therapeutics (ARCT) on the GURU.Markets platform reflects the dynamics of a company developing cutting-edge drugs based on the LUNAR system to combat orphan diseases. Business revenues are based on licensing royalties and payments from CSL for vaccination, as well as liver disease therapies. The current ratio is 6.03, while a stable cash flow is ensured through long-term agreements with major industry players.

Developing mRNA vaccines in partnership with the public sector requires significant expenditures, making the control of available funds, excluding inventories, critically important. The ratio of cash and accounts receivable to current liabilities, reflected in the quick ratio, allows for an assessment of Arcturus Therapeutics (ARCT) resilience to cash flow gaps and the impact of liquidity risks on the cost of capital.